{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:38:19Z","timestamp":1788305899160,"version":"build-2803163510"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:p>5 Alpha Reductase Inhibitor (ARI) is a widely used class of medication; for benign prostatic hypertrophy, androgenetic alopecia and hirsutism. While generally considered safe, ARIs class of medication does have a number of side effects, which can sometimes persist long after discontinuation of the medication. Since this class of medication is generally thought of as being benign, it can be overlooked as a potential cause of new clinical symptoms patients might experience. The purpose of this review is to alert primary care physicians to the more common side effects, so as to always keep adverse drug reaction related to 5ARI as a cause of new symptoms, when evaluating patients, young and old.<\/jats:p>","DOI":"10.4103\/jfmpc.jfmpc_575_24","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T04:00:34Z","timestamp":1731729634000},"page":"4797-4799","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Using 5 alpha reductase inhibitors safely: What primary care physicians need to know"],"prefix":"10.4103","volume":"13","author":[{"given":"Senthil R.","family":"Meenrajan","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Florida, Gainesville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"R1-20250129","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/jc.2003-030330","article-title":"Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 alpha-reductase inhibitor","volume":"89","author":"Clark","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"(Suppl 1)","key":"R2-20250129","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1046\/j.1464-410X.1998.0820s1034.x","article-title":"Population-based studies of the epidemiology of benign prostatic hyperplasia","volume":"82","author":"Girman","year":"1998","journal-title":"Br J Urol"},{"key":"R4-20250129","doi-asserted-by":"crossref","first-page":"487","DOI":"10.21037\/tau-22-690","article-title":"5-alpha reductase inhibitors use in prostatic disease and beyond","volume":"12","author":"Chislett","year":"2023","journal-title":"Transl Androl Urol"},{"key":"R5-20250129","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0022-5347(01)62141-4","article-title":"Selectivity of finasteride as an in vivo inhibitor of 5 alpha-reductase isozyme enzymatic activity in the human prostate","volume":"161","author":"Span","year":"1999","journal-title":"J Urol"},{"key":"R6-20250129","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jsxm.2016.07.006","article-title":"Effect of 5a-reductase inhibitors on sexual function:A meta-analysis and systematic review of randomized controlled trials","volume":"13","author":"Liu","year":"2016","journal-title":"J Sex Med"},{"key":"R7-20250129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.fertnstert.2019.11.030","article-title":"Post-finasteride syndrome:A surmountable challenge for clinicians","volume":"113","author":"Traish","year":"2020","journal-title":"Fertil Steril"},{"key":"R8-20250129","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.abd.2020.02.001","article-title":"Post-finasteride syndrome","volume":"95","author":"Pereira","year":"2020","journal-title":"An Bras Dermatol"},{"key":"R9-20250129","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s12035-015-9315-y","article-title":"Low testosterone level and risk of alzheimer's disease in the elderly men:A systematic review and meta-analysis","volume":"53","author":"Lv","year":"2016","journal-title":"Mol Neurobiol"},{"key":"R10-20250129","doi-asserted-by":"crossref","first-page":"e2248135","DOI":"10.1001\/jamanetworkopen.2022.48135","article-title":"Association of 5a-reductase inhibitors with dementia, depression, and suicide","volume":"5","author":"Garcia-Argibay","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R11-20250129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jns.2017.05.064","article-title":"The risk of dementia with the use of 5 alpha reductase inhibitors","volume":"379","author":"Welk","year":"2017","journal-title":"J Neurol Sci"},{"key":"R12-20250129","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/CND.0b013e3181873cca","article-title":"Finasteride-induced myalgia and HyperCKemia","volume":"10","author":"Al-Harbi","year":"2008","journal-title":"J Clin Neuromuscul Dis"},{"key":"R14-20250129","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/pds.4383","article-title":"Risk of rhabdomyolysis from 5-a reductase inhibitors","volume":"27","author":"Welk","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R15-20250129","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MOU.0000000000000464","article-title":"Prostate cancer prevention with 5-alpha reductase inhibitors:Concepts and controversies","volume":"28","author":"Liss","year":"2018","journal-title":"Curr Opin Urol"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_575_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:29:58Z","timestamp":1787837398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_575_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_575_24","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"2024-04-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}